Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

University of Toronto

$121,000.00

Oxadiazole grafts in peptide macrocycles

EF 2017-18

Résumé
In 2016, we discovered a macrocyclization reaction that rapidly converts readily accessible linear peptides into macrocycles with well-defined conformation. (N-isocyanimino)triphenylphosphorane, instrumental to this reaction, was later named ""Pinc"" to identify the presence of phosphonium and isocyanide functionalities. This work was published in Nature Chemistry and was subsequently covered by The Chemical & Engineering News and Science. On the heels of this discovery, we applied for a patent application (PCT/CA2016/000234) that described the method of cyclizing peptides with simultaneous incorporation of an oxadiazole graft into the resulting macrocyclic structures. We also received market assessment funding from NSERC allowing us to retain the services of Adventus Research who carried out a thorough market assessment study (see the 85-page report attached).The present I2I application considers the main messages from that report and focuses on two applications that will further de-risk our technology now that it is sufficiently mature. The first one is to develop an approach to the synthesis of improved derivatives of Pinc. The second one deals with peptide macrocycles produced using Pinc in order to further validate our approach to novel composition of matter. To move forward, we will engage in collaborative activity to produce Pinc (together with MilliporeSigma), initiate translational studies aimed at the use of Pinc toward heterocycle synthesis (together with Apotex), and evaluate the potential of Pinc-derived macrocycles in drug discovery (together with Encycle and Merck).
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
516247-2017
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
121000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Oxadiazole grafts in peptide macrocycles
Keyword
NSERC
Application summary
In 2016, we discovered a macrocyclization reaction that rapidly converts readily accessible linear peptides into macrocycles with well-defined conformation. (N-isocyanimino)triphenylphosphorane, instrumental to this reaction, was later named ""Pinc"" to identify the presence of phosphonium and isocyanide functionalities. This work was published in Nature Chemistry and was subsequently covered by The Chemical & Engineering News and Science. On the heels of this discovery, we applied for a patent application (PCT/CA2016/000234) that described the method of cyclizing peptides with simultaneous incorporation of an oxadiazole graft into the resulting macrocyclic structures. We also received market assessment funding from NSERC allowing us to retain the services of Adventus Research who carried out a thorough market assessment study (see the 85-page report attached).The present I2I application considers the main messages from that report and focuses on two applications that will further de-risk our technology now that it is sufficiently mature. The first one is to develop an approach to the synthesis of improved derivatives of Pinc. The second one deals with peptide macrocycles produced using Pinc in order to further validate our approach to novel composition of matter. To move forward, we will engage in collaborative activity to produce Pinc (together with MilliporeSigma), initiate translational studies aimed at the use of Pinc toward heterocycle synthesis (together with Apotex), and evaluate the potential of Pinc-derived macrocycles in drug discovery (together with Encycle and Merck).